Abstract
Twenty-six transplanted thalassemic patients out of 295 analyzed, showed the presence of persistent mixed chimerism, over a period of time varying between 2 and 11 years after BMT. Despite the presence of large numbers of residual host cells, these transplanted thalassemic patients no longer require red blood cell transfusions and have a functional graft, producing sufficient levels of hemoglobin A ranging from 8.3–14.7 g/dl. These ex-thalassemic patients with persistent mixed chimerism, although they did not achieve complete donor engraftment are no longer exposed to the risk of graft rejection. The mechanisms underlying this apparent state of tolerance or education in these patients are at the present time unknown. However, these observations may be useful for physicians involved in defining optimal strategies for clinical gene therapy, in uterohematopoietic stem cell transplantation and adoption of less toxic conditioning regimens in mini-transplantation. Bone Marrow Transplantation (2000) 25, 401–404.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hill RS, Petersen FB, Storb R et al. Mixed hematologic chimerism after allogenic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease Blood 1986 67: 811–816
Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia Blood 1996 87: 3494–3499
Lucarelli G, Clift R, Galimberti M et al. Bone marrow transplantation in adult thalassemic patients Blood 1999 93: 1164–1167
Lucarelli G, Galimberti M, Giardini C et al. Bone marrow transplantation in thalassemia. The experience of Pesaro Ann NY Acad Sci 1998 850: 270–275
Sharabi Y, Abraham VS, Sykes M, Sachs D . Mixed allogeneic chimerism prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance Bone Marrow Transplant 1992 9: 191–197
Slavin S, Nagler A, Napastek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
Dentamaro T, Cudillo L, Picardi A et al. Allogenic stem cell transplantation after non-myeloablative conditioning for poor risk patients with hematologic malignancies Bone Marrow Transplant 1998 21: (Suppl. 1) 115
Nesci S, Manna M, Andreani M et al. Mixed chimerism in thalassemic patients after bone marrow transplantation Bone Marrow Transplant 1992 10: 143–147
Smith AJ, Martin P, McFarland C et al. Evaluation of engraftment in the stem cell transplant setting by PCR DNA amplification and analysis of variable number tandem repeat loci ASHI Quart 1998 22: 3–9
Petz LD, Yam P, Wallace RB et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies Blood 1987 70: 1331–1337
Bertheas MF, Lafage M, Levy P et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia Blood 1991 78: 3103–3107
Huss R, Deeg H, Gooley T et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplasticanemia or chronic myelogenous leukemia Bone MarrowTransplant 1996 18: 767–776
Aker M, Kapelushnik J, Pugatsch T et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major J Pediatr Hematol Oncol 1998 20: 145–148
Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433–444
Elwood E, Larsen C, Maurer D et al. Microchimerism and rejection in clinical transplantation Lancet 1997 349: 1358–1360
Flake A, Zanjani E . In utero hematopoietic stem cell transplantation JAMA 1997 278: 932–937
Acknowledgements
We thank Dr Stanley Shrier for stimulating discussion and reviewing of the manuscript. This study was supported by the Berloni Foundation against Thalassemia, Pesaro, Italy.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andreani, M., Nesci, S., Lucarelli, G. et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 25, 401–404 (2000). https://doi.org/10.1038/sj.bmt.1702151
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702151
Keywords
This article is cited by
-
Unmanipulated Stem Cell Boost for Mixed Chimerism in Transfusion Dependent Thalassemia
Indian Journal of Hematology and Blood Transfusion (2021)
-
Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells
Nature Medicine (2021)
-
Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation
Nature Communications (2019)
-
Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide
Bone Marrow Transplantation (2018)
-
In utero nanoparticle delivery for site-specific genome editing
Nature Communications (2018)
